30 325

Cited 48 times in

Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy.

Authors
Lee, HW; Choi, YW; Han, JH; Kim, JH; Jung, JH; Jeong, SH; Kang, SY; Choi, JH; Oh, YT; Park, KJ; Hwang, SC; Sheen, SS
Citation
Lung cancer (Amsterdam, Netherlands), 65(3):377-382, 2009
Journal Title
Lung cancer (Amsterdam, Netherlands)
ISSN
0169-50021872-8332
Abstract
PATIENTS AND METHODS: Pretreatment tumor biopsy specimens from 50 patients with NSCLC including stage IIIB with malignant pleural effusion or stage IV or recurrent disease were analyzed for p53, Bcl-2, Bax, and ERCC1 expression by immunohistochemistry. All patients were treated with platinum-based third-generation doublet chemotherapy, in which gemcitabine and cisplatin was the most commonly administered regimen (17 patients). RESULTS: High expression of p53, Bcl-2, Bax, and ERCC1 was observed in 24 (48%), 8 (16%), 32 (63%), and 28 (55%) patients, respectively. In univariate analysis, high expression of ERCC1 demonstrated a trend of association with poor overall survival (OS) (median, 8 months vs. 11 months; P=0.055). High expression of p53, Bcl-2, Bax was not correlated with patient outcome. High expression of ERCC1 was an independent prognostic factor for poor OS (P=0.002) along with poor performance status (P=0.028) and lack of disease control (P=0.001) in multivariate analysis. CONCLUSIONS: High expression of ERCC1 may be a useful prognostic factor for poor outcome in advanced NSCLC patients treated with platinum and third-generation doublet chemotherapy.
MeSH terms
AdultAgedAntineoplastic Combined Chemotherapy Protocols/therapeutic use*Carcinoma, Non-Small-Cell Lung/diagnosisCarcinoma, Non-Small-Cell Lung/drug therapy*Carcinoma, Non-Small-Cell Lung/mortalityCarcinoma, Non-Small-Cell Lung/pathologyCarcinoma, Non-Small-Cell Lung/physiopathologyCisplatin/administration & dosageDNA-Binding Proteins/geneticsDNA-Binding Proteins/metabolism*Deoxycytidine/administration & dosageDeoxycytidine/analogs & derivativesDisease ProgressionDrug Resistance, NeoplasmEndonucleases/geneticsEndonucleases/metabolism*FemaleHumansImmunohistochemistryLung Neoplasms/diagnosisLung Neoplasms/drug therapy*Lung Neoplasms/mortalityLung Neoplasms/pathologyLung Neoplasms/physiopathologyMaleMiddle AgedNeoplasm StagingPlatinum/administration & dosagePleural Effusion, Malignant/diagnosisPleural Effusion, Malignant/drug therapy*Pleural Effusion, Malignant/mortalityPleural Effusion, Malignant/pathologyPleural Effusion, Malignant/physiopathologyPrognosisProto-Oncogene Proteins c-bcl-2/geneticsProto-Oncogene Proteins c-bcl-2/metabolismRecurrenceSurvival AnalysisTreatment OutcomeTumor Suppressor Protein p53/geneticsTumor Suppressor Protein p53/metabolismbcl-2-Associated X Protein/geneticsbcl-2-Associated X Protein/metabolism
DOI
10.1016/j.lungcan.2008.12.005
PMID
19150580
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Hematology-Oncology
Journal Papers > School of Medicine / Graduate School of Medicine > Pathology
Journal Papers > School of Medicine / Graduate School of Medicine > Plastic & Reconstructive Surgery
Journal Papers > School of Medicine / Graduate School of Medicine > Radiation Oncology
Journal Papers > School of Medicine / Graduate School of Medicine > Pulmonary & Critical Care Medicine
Journal Papers > School of Medicine / Graduate School of Medicine > Medical Science
AJOU Authors
이현우한재호김장희정재호정성현강석윤최진혁오영택박광주황성철신승수
Full Text Link
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse